•
Dec 31, 2024
•/
Nyxoah SA Q4 2024 Earnings Report
Nyxoah reported revenue growth but higher operating losses in Q4 2024.
Key Takeaways
Nyxoah's Q4 2024 revenue reached €1.3 million, with a gross margin of 73%. However, increased research and development expenses contributed to a higher operating loss of €18.3 million. The company is preparing for its U.S. commercial launch in March 2025, following anticipated FDA approval.
Total revenue was €1.3 million, impacted by deferred revenue recognition.
Gross margin improved to 73%, up from 60% in Q4 2023.
Operating loss widened to €18.3 million due to increased R&D spending.
Cash and financial assets increased to €85.6 million from €57.7 million YoY.
Nyxoah SA
Nyxoah SA
Nyxoah SA Revenue by Segment
Forward Guidance
Nyxoah expects significant growth in 2025, driven by the anticipated U.S. commercial launch of Genio and further expansion in European markets.
Positive Outlook
- FDA approval for Genio expected by the end of Q1 2025.
- Commercial launch in the U.S. scheduled for March 2025.
- Strong cash position of €85.6 million to support expansion.
- Growing demand for Genio in European markets, particularly Germany.
- Continued progress in clinical trials to expand treatment applications.
Challenges Ahead
- High R&D expenses continue to impact profitability.
- Regulatory risks related to FDA approval timeline.
- Uncertain reimbursement landscape in the U.S.
- Significant competition in the OSA treatment market.
- Potential delays in scaling commercial operations.